title: Bevacizumab and other targeted agents in the upfront treatment of glioblastoma.
abstract: The standard treatment for glioblastoma, the most common primary malignant brain tumor, has been maximal safe surgical resection followed by the combination of radiation and temozolomide. Bevacizumab has shown promise in the treatment of glioblastoma; it and a number of other new, targeted agents have been tested in combination with radiation and temozolomide. Results of recent studies of such agents are discussed. Although many of these agents show promise, none as yet has established a new standard of care for these difficult-to-treat tumors.
authors.affiliation: Department of Neurology, University of California, San Francisco, CA; Department of Neurological Surgery, University of California, San Francisco, CA. Electronic address: clarkej@neurosurg.ucsf.edu.
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Clarke
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy*; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab